Global Mitochondrial Myopathies Treatment Market - 2022-2029

Global Mitochondrial Myopathies Treatment Market - 2022-2029

Market Overview

The global mitochondrial myopathies treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Mitochondrial disorders are inherited chronic conditions marked by a variety of biochemical and genetic mitochondrial abnormalities and mutations. The condition affects the brain, heart, liver, skeletal muscles, kidneys, and respiratory systems, among other organs. Patients with mitochondrial disorders frequently experience muscle weakness, exercise intolerance, and weariness as a result of a reduction in mitochondrial respiration caused by mitochondrial DNA abnormalities that result in a decreased ability to synthesize cellular adenosine triphosphate (ATP). The majority of vitamins, co-factors, off-label medications approved for other reasons, and nutritional supplements are used to treat mitochondrial problems.

Market Dynamics

Innovative therapies in the clinical trials for the treatment of Mitochondrial Myopathies are expected to drive market growth.

Mitochondrial illnesses are genetically based, neither metabolic pathways nor symptomatic treatments can fundamentally fix them. Gene therapy is therefore the best option. Most advances in mitochondrial disease gene therapy have so far been focused on LHON. Pathogenic mutations of the mtDNA encoding complex IV subunit 4 are seen in about 70% of people with LHON (MT-ND4). The adeno-associated virus (AAV) can transport mtDNA, and its capsid VP2 can fuse with a plasmid targeting sequence to reexpress ND4. The expression of wild-type ND4 in ND4 mutant cells can help to correct ATP production problems. Moreover, This is the first time gene-editing technology has been used to change mtDNA in vivo, indicating that gene-editing technologies are utilized to treat mitochondrial illnesses.

Furthermore, research has shown considerable promise and is predicted to result in more effective treatment techniques for mitochondrial illnesses. Mitochondrial biogenesis enhancers (bezafibrate, epicatechin, and RTA 408), antioxidants (RP 103 and EPI-743), and cardiolipin protectors are among the medications now being studied (elamipretide). Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Higher R&D costs, more stringent drug approval restrictions, and a lack of knowledge and understanding of the condition are some of the factors expected to hamper the market growth in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 is extremely contagious in older people with weakened immune systems, and the risk of death rises with age and the presence of comorbidities including hypertension, diabetes, cardiovascular disease, or chronic obstructive pulmonary disease. There are several theories regarding mitochondria and their functions in inflammation that could explain why SARS-CoV-2 is wreaking havoc on the older population, particularly those with comorbidities. As a result, the importance of mitochondria in treatment development has increased. Over-stimulated or sustained inflammatory responses with interferon and cytokine production, regulation of fission and fusion, mitochondrial biogenesis, and interference with apoptosis and mitophagy are all possible linkages between aging mitochondria and reduced immunity. From bacteria to parasites to viruses like SARS-CoV-2, many pathogens have shown a predisposition to disrupt mitochondria as a strategy to influence host behavior once inside a cell by changing their processes.

Additionally, the pandemic interrupts the supply chain and clinical trials process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Others segment is expected to hold the largest market share in mitochondrial myopathies treatment market

The others segment is expected to dominate in 2021. The segment is bifurcated into Mito Cocktail, Exercise, and Mitochondrial Replacement Therapy (MRT). Moreover, there is no cure for mitochondrial abnormalities, there are several treatments that might help relieve symptoms. Treatments differ from person to person and are dependent on the type of mitochondrial dysfunction that has been detected. The Mito Cocktail consists of a combination of vitamin supplements such as acetyl-L-carnitine (ALCAR), coenzyme Q10 (CoQ10), and alpha-lipoic acid (ALA), and creatine monohydrate, which is the most common form of treatment (CM). It is a scientifically based mix of vitamins, cofactors, and nutrients that are known to replace deficits that develop when the mitochondrial energy production system fails and to improve the residual function of the mitochondrial energy production system.

Additionally, One of the most useful medicines is exercise, which has been clinically verified (as long as the patient can tolerate it). On a biological level, exercise boosts energy production, which enhances mitochondrial function and increases the number of healthy mitochondria in the cells. According to studies, exercise improves exercise tolerance and metabolism by allowing the body to use oxygen more efficiently. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global mitochondrial myopathies treatment market

In 2021, North America accounted for the highest revenue share. With the increasing prevalence of Mitochondrial Myopathies, rising demand for mitochondrial-based therapeutics, advancements in diagnostic facilities, and rising number of clinical trials to develop effective drugs for the disease along with the rise in several FDA approvals for novel drugs and therapies in the region are some of the factors the market is expected to boost in the forecast period. For instance, Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) are one of the most common mitochondrial diseases, with an estimated incidence of 1 in 4000, and mitochondria are carried out in the tails of sperm cells and hence discharged outside the zygote during fertilization, only women may pass the disease on to their children.

Moreover, The North American Mitochondrial Disease Consortium (NAMDC), which is part of the Rare Disease Clinical Research Network (RDCRN), collects information from mitochondrial disease patients in a clinical patient registry, which aids researchers in finding and recruiting participants for future studies. Additionally, The US Food and Drug Administration granted orphan therapeutic status to Reneo Pharmaceutical's main drug candidate REN001, to treat primary mitochondrial myopathy in June 2020. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the mitochondrial myopathies treatment market are Pfanstiehl, Inc., Ajinomoto Co., Inc., BOTAY BIO-CHEM CO., LIMITED, Xi'an ZB Biotech Co., Ltd., Kaneka Corporation, Lonza, AdvaCare Pharma and NutraBio Labs, Inc.

Lonza Group:

Overview:

Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology, and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America, and South Asia. The company provides product development services to the pharmaceutical and biologics industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.

­Product Portfolio:

Carnipure: Carnipure L-Carnitine is the nutrient needed to help support conversion of fat into metabolic energy. It provides benefits ranging from increasing blood flow, reducing markers of metabolic stress, decreasing muscle soreness and improving recovery time.

Why Purchase the Report?

Visualize the composition of the mitochondrial myopathies treatment market segmentation by type, test type, drug type, treatment type, distribution channel and region highlighting the key commercial assets and players.

Identify commercial opportunities in mitochondrial myopathies treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of mitochondrial myopathies treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global mitochondrial myopathies treatment market report would provide an access to an approx. 45+market data table, 40+figures and 200pages